<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473508</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2018/PC-02</org_study_id>
    <nct_id>NCT04473508</nct_id>
  </id_info>
  <brief_title>Erectus Nerve Block for Lumbar Spine Surgery</brief_title>
  <acronym>EFABE</acronym>
  <official_title>Erectus Nerve Block for Lumbar Spine Surgery : a Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      : Spine surgery induced severe postoperative pain. Several techniques as intravenous
      multimodal analgesia have been proposed to reduce pain relief and morphine rescue over the
      first postoperative days. Regional anesthesia using the erectus nerve block is a simple
      infiltration across lamina of the vertebra: Ultrasound-guided posterior ramus of spinal nerve
      block for anesthesia and analgesia in lumbar spinal surgery This study compared erector nerve
      block with local anesthetic vs placebo to reduce pain and morphine rescue after lumbar spine
      surgery. The investigators hypothesized that eructor nerve block induced a large block from
      L1 to L5 that induced posterior nerve roots block anesthesia. This block reduced pain after
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption (mg)</measure>
    <time_frame>24 Hours after surgery</time_frame>
    <description>Quantity administered in the post-interventional monitoring room and in hospitalization via a self-controlled morphine pump by the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from surgery to 3 months</time_frame>
    <description>Nausea, vomiting, confusion, urinary retention, hematoma, reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain at rest and at movement: Visual Analogic scale</measure>
    <time_frame>Day 1 to Day 3, Day od hospital discharge and month 3</time_frame>
    <description>Visual Analogic scale of pain (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic pain: DN4 questionnaire</measure>
    <time_frame>Questionnaire DN4 at 3 months</time_frame>
    <description>pain score as mesured with DN4 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>hospital length of stay, an average of 4 days</time_frame>
    <description>Number of day in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the post-intervention care unit</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of minutes that patient stay in post intervention care unit in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction: visual analogic scale</measure>
    <time_frame>Day of hospital discharge, an average of day 4</time_frame>
    <description>Patient satisfaction mesured with a visual analogic scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of life: EQ-5D Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Patient Quality of life mesured with EQ-5D Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Spine Surgery</condition>
  <condition>Pain Relief</condition>
  <condition>Morphine</condition>
  <condition>AdverseEvent</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Local administration of Placebo ( Saline Solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local administration of ropivacaine</intervention_name>
    <description>Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery</description>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local administration of placebo (saline solution)</intervention_name>
    <description>injection of saline solution in addition with conventional anesthesia for spine surgery</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt; 18years and &lt;80 years

          -  lumbar spine surgery (2-4 levels)

          -  posterior approach

          -  ASA 1-3

        Exclusion Criteria:

          -  refusal

          -  age &lt; 18yrs

          -  &lt;50 kg and &gt;120 kg

          -  pregnant

          -  renal or hepatic severe desease

          -  ASA 4

          -  no French speaking

          -  emergency surgery

          -  local or systemic infection

          -  surgical resumption of the surgical site

          -  surgery involving a thoracic approach

          -  allergy to local anesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Avis, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geoffrey.avis@chu-nimes.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe CUVILLON, PD PhD</last_name>
    <phone>+334466683050</phone>
    <email>philippe.cuvillon@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natacha SIMON</last_name>
    <phone>+334466686819</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>philippe cuvillon, MD,PhD</last_name>
      <phone>4-66-68-30-50</phone>
      <phone_ext>33</phone_ext>
      <email>philippe.cuvillon@chu-nimes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

